Paper Details

  1. Home
  2. Paper Details

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.

Author: AledortLouis M, BusselJames B, CukerAdam, KesslerCraig M, KuterDavid J, McIntoshJoe, PendergrassKelly B, TangShande

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This 28-day phase 2 study investigated the efficacy and safety of avatrombopag, a nonpeptide thrombopoietin-receptor agonist, in patients with immune thrombocytopenia (ITP). The study found that avatrombopag was effective in increasing platelet counts and was generally well tolerated, with similar response rates and side effects to other TPO-RAs.
Paper Details　
Original Abstract of the Article :
Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effective second-line treatment in immune thrombocytopenia (ITP). This 28-day phase 2 study assigned subjects with ITP of ≥3 months to once-daily oral avatrombopag (2.5, 5, 10, or 20 mg), an investigational nonpep...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1182/blood-2013-07-514398

データ提供：米国国立医学図書館（NLM）

Avatrombopag: A New Oasis in the Desert of ITP Treatment

Immune thrombocytopenia (ITP) is a condition where the body destroys its own platelets, leading to easy bruising and bleeding. This study investigates a new drug called avatrombopag, which helps boost platelet production.

Boosting Platelet Production: A New Hope for ITP Patients

Avatrombopag showed impressive results in increasing platelet counts in patients with ITP. The drug was generally well-tolerated, with side effects similar to other drugs in this class. While the study was relatively short, the findings suggest that avatrombopag could be a valuable new treatment option for ITP.

Navigating the ITP Landscape: A Guide for Patients

This study is a reminder that there are new and promising treatments for ITP. It's important to talk to your doctor about all your treatment options and find the one that's right for you. Keep in mind that ITP is a complex condition, and there may be ups and downs in your journey, but with persistence and a supportive medical team, you can find your way through the desert.

Dr.Camel's Conclusion

Avatrombopag emerges as a promising treatment for ITP, effectively boosting platelet production and offering hope for those living with this condition. The study's findings provide a beacon of hope for ITP patients and underscore the importance of ongoing research in developing new and improved treatments.

Date :
  1. Date Completed 2014-09-02
  2. Date Revised 2021-02-02
Further Info :

Pubmed ID

24802775

DOI: Digital Object Identifier

10.1182/blood-2013-07-514398

Related Literature

Article Analysis
・Effects of avatrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.